Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global ACE Inhibitors Market, by Drug
1.1.2. Global ACE Inhibitors Market, by Application
1.1.3. Global ACE Inhibitors Market, by Dosage Form
1.1.4. Global ACE Inhibitors Market, by Distribution Channel
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Research Methodology for Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.2.1. R&D and Designing
5.2.2. Manufacturing
5.2.3. Distribution & Sales
5.2.4. Post Sales Services
6. GLOBAL ACE INHIBITORS MARKET, BY DRUG
6.1. Overview
6.2. Lisinopril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Ramipril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Enalapril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Benazepril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6. Fosinopril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.7. Captopril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.8. Moexipril
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.9. Others
7. GLOBAL ACE INHIBITORS MARKET, BY APPLICATION
7.1. Overview
7.2. Heart Failure
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Hypertension
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Diabetes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Heart Attack
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.6. Chronic Kidney Disease
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.7. Others
8. GLOBAL ACE INHIBITORS MARKET, BY DOSAGE FORM
8.1. Overview
8.2. Oral Tablets
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Oral Solution
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL
9.1. Overview
9.2. Retail Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.3. Hospital Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.4. E-commerce Websites and Online Drug Stores
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10. GLOBAL ACE INHIBITORS MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. Italy
10.3.1.4. Spain
10.3.1.5. UK
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPANY LANDSCAPE
11.1. Overview
11.2. Competitor Dashboard
11.3. Major Growth Strategy in the Global ACE Inhibitors Market
11.4. Competitive Benchmarking
11.5. The Leading Player in terms of Number of Developments in the Global ACE Inhibitors Market
11.6. Key Developments & Growth Strategies
11.6.1. New Product Launch/Service Deployment
11.6.2. Merger & Acquisition
11.6.3. Joint Ventures
11.7. Major Players Financial Matrix & Market Ratio
11.7.1. Sales & Operating Income 2020
11.7.2. Major Players R&D Expenditure 2020
12. COMPANY PROFILES
12.1. Bristol-Myers Squibb Company
12.1.1. Company Overview
12.1.2. Products/Services Offered
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Par Pharmaceutical Companies, Inc.
12.3. UCB, Inc.
12.4. Pfizer, Inc.
12.5. AbbVie Inc.
12.6. AstraZeneca
12.7. Bausch Health Companies, Inc.
12.8. Novartis AG
12.9. Merck & Co., Inc.
12.10. Teva Pharmaceutical Industries Ltd.
12.11. Silvergate Pharmaceuticals, Inc.
12.12. Others
13. APPENDIX
13.1. References
13.2. Related Reports
NOTE:
This table of content is tentative and subject to change as the research progresses.
ï‚¡ In section 12, only the top 10 companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
ï‚¡ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
LIST OF TABLES
TABLE 1 GLOBAL ACE INHIBITORS MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL ACE INHIBITORS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 7 GLOBAL ACE INHIBITORS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 10 NORTH AMERICA: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 11 NORTH AMERICA: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 12 US: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 13 US: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 14 US: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 15 US: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 16 CANADA: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 17 CANADA: ACE INHIBITORS MARKET, BY APPLICATION 2020-2027 (USD MILLION)
TABLE 18 CANADA: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 19 CANADA: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 20 LATIN AMERICA: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 21 LATIN AMERICA: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 22 LATIN AMERICA: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 23 LATIN AMERICA: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 24 EUROPE: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 25 EUROPE: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 26 EUROPE: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 27 EUROPE: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 28 WESTERN EUROPE: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 29 WESTERN EUROPE: ACE INHIBITORS MARKET, BY APPLICATION 2020-2027 (USD MILLION)
TABLE 30 WESTERN EUROPE: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 31 WESTERN EUROPE: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 32 EASTERN EUROPE: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 33 EASTERN EUROPE: ACE INHIBITORS MARKET, BY APPLICATION 2020-2027 (USD MILLION)
TABLE 34 EASTERN EUROPE: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 35 EASTERN EUROPE: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA: ACE INHIBITORS MARKET, BY DRUG, 2020-2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: ACE INHIBITORS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: ACE INHIBITORS MARKET, BY DOSAGE FORM, 2020-2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: ACE INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ACE INHIBITORS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ACE INHIBITORS MARKET
FIGURE 4 GLOBAL ACE INHIBITORS MARKET SHARE, BY DRUG, 2020 (%)
FIGURE 5 GLOBAL ACE INHIBITORS MARKET SHARE, BY APPLICATION 2020 (%)
FIGURE 6 GLOBAL ACE INHIBITORS MARKET SHARE, BY DOSAGE FORM 2020 (%)
FIGURE 7 GLOBAL ACE INHIBITORS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)
FIGURE 8 GLOBAL ACE INHIBITORS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 AMERICAS: ACE INHIBITORS MARKET SHARE BY REGION, 2020 (%)
FIGURE 10 NORTH AMERICA: ACE INHIBITORS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 EUROPE: ACE INHIBITORS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 12 WESTERN EUROPE: ACE INHIBITORS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 ASIA-PACIFIC: ACE INHIBITORS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 MIDDLE EAST & AFRICA: ACE INHIBITORS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 15 GLOBAL ACE INHIBITORS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 16 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE
FIGURE 19 PAR PHARMACEUTICAL COMPANIES, INC.: KEY FINANCIALS
FIGURE 20 PAR PHARMACEUTICAL COMPANIES, INC.: SEGMENTAL REVENUE
FIGURE 21 PAR PHARMACEUTICAL COMPANIES, INC.: REGIONAL REVENUE
FIGURE 22 UCB, INC.: KEY FINANCIALS
FIGURE 23 UCB, INC.: SEGMENTAL REVENUE
FIGURE 24 UCB, INC.: REGIONAL REVENUE
FIGURE 25 PFIZER, INC.: KEY FINANCIALS
FIGURE 26 PFIZER, INC.: SEGMENTAL REVENUE
FIGURE 27 PFIZER, INC.: REGIONAL REVENUE
FIGURE 28 ABBVIE INC.: KEY FINANCIALS
FIGURE 29 ABBVIE INC.: SEGMENTAL REVENUE
FIGURE 30 ABBVIE INC.: REGIONAL REVENUE
FIGURE 31 ASTRAZENECA: KEY FINANCIALS
FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 33 ASTRAZENECA: REGIONAL REVENUE
FIGURE 34 BAUSCH HEALTH COMPANIES INC.: KEY FINANCIALS
FIGURE 35 BAUSCH HEALTH COMPANIES INC.: SEGMENTAL REVENUE
FIGURE 36 BAUSCH HEALTH COMPANIES INC.: REGIONAL REVENUE
FIGURE 37 NOVARTIS AG: KEY FINANCIALS
FIGURE 38 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 39 NOVARTIS AG: REGIONAL REVENUE
FIGURE 40 MERCK & CO., INC.: KEY FINANCIALS
FIGURE 41 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 42 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIALS
FIGURE 44 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SEGMENTAL REVENUE
FIGURE 45 TEVA PHARMACEUTICAL INDUSTRIES LTD.: REGIONAL REVENUE
FIGURE 46 SILVERGATE PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 47 SILVERGATE PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 48 SILVERGATE PHARMACEUTICALS, INC.: REGIONAL REVENUE
